Address: The Magdalen Centre,Oxford Science Park,Oxford, OX4 4GA
Tel: +44 (0)1865 784255
Founded in 2006, EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $2 billion company by the middle of this decade.
Products and services
The company currently has nine products on the market, including Erwinase® and Kidrolase® for treatment of acute lymphoblastic leukemia, Caphosol® for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, the antibiotic surgical implant Collatamp®, ProstaScint® for imaging the extent and spread of prostate cancer, and Quadramet® for the treatment of pain in patients whose cancer has spread to the bones. EUSA also has several products in late-stage development.